Serum CA 15.3, CEA and ESR patterns in breast cancer.
Serum CA 15.3, CEA and ESR were longitudinally determined in 298 patients with breast cancer during postsurgical follow-up and/or therapy. Observation lasted until the death of the patient or at least for three years. With regards to longitudinal serum markers and ESR curves, four different patterns have been identified: pattern I: the markers and ESR stayed at normal levels; pattern II: the markers and ESR decreased from a peak level; pattern III: the markers and ESR fluctuated widely; pattern IV: the markers and ESR increased steadily. We have looked at over all survival (OS) and relapse-free survival ( RFS) versus longitudinal CA 15.3, CEA and ESR patterns. Univariate Cox regression analysis showed that OS and RFS were significantly associated with all four patterns.
Rubach
M
M
Chemotherapy Outpatient Department, Cancer Center-Institute, Warsaw, Poland.
Szymendera
J J
JJ
Kamińska
J
J
Kowalska
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001799:Blood Sedimentation; D001943:Breast Neoplasms / Q000097:blood* / Q000401:mortality; D002272:Carcinoembryonic Antigen / Q000097:blood*; D002277:Carcinoma / Q000097:blood* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D009363:Neoplasm Proteins / Q000097:blood*; D011044:Poland / Q000453:epidemiology; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D009363:Neoplasm Proteins